CO6311002A2 - Agentes fijadores y epitopos wise - Google Patents

Agentes fijadores y epitopos wise

Info

Publication number
CO6311002A2
CO6311002A2 CO10075718A CO10075718A CO6311002A2 CO 6311002 A2 CO6311002 A2 CO 6311002A2 CO 10075718 A CO10075718 A CO 10075718A CO 10075718 A CO10075718 A CO 10075718A CO 6311002 A2 CO6311002 A2 CO 6311002A2
Authority
CO
Colombia
Prior art keywords
epithopes
fixing agents
wise
wise fixing
agents
Prior art date
Application number
CO10075718A
Other languages
English (en)
Spanish (es)
Inventor
Xueming Qian
Kevin Graham
Li Zhang
Aaron George Winter
Mei-Mei Tsai
Barbara S Tipton
Grant Shimamoto
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CO6311002A2 publication Critical patent/CO6311002A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CO10075718A 2007-11-21 2010-06-23 Agentes fijadores y epitopos wise CO6311002A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US403707P 2007-11-21 2007-11-21

Publications (1)

Publication Number Publication Date
CO6311002A2 true CO6311002A2 (es) 2011-08-22

Family

ID=40524859

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10075718A CO6311002A2 (es) 2007-11-21 2010-06-23 Agentes fijadores y epitopos wise

Country Status (17)

Country Link
US (2) US8043620B2 (https=)
EP (1) EP2220118A2 (https=)
JP (2) JP5583591B2 (https=)
KR (1) KR20100099193A (https=)
CN (1) CN101925611A (https=)
AU (1) AU2008330125B2 (https=)
BR (1) BRPI0820387A2 (https=)
CA (1) CA2705879A1 (https=)
CO (1) CO6311002A2 (https=)
CR (1) CR11523A (https=)
EA (1) EA201000844A1 (https=)
IL (1) IL205569A0 (https=)
MA (1) MA31918B1 (https=)
MX (1) MX2010005656A (https=)
TN (1) TN2010000213A1 (https=)
WO (1) WO2009070243A2 (https=)
ZA (1) ZA201003578B (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1771470B1 (en) 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
KR20190006086A (ko) 2005-11-23 2019-01-16 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒⅱａ 길항제 및 골 성장을 촉진하기 위한 이들의 용도
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2111229B1 (en) 2007-02-01 2013-04-10 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
ES2756725T3 (es) 2007-02-09 2020-04-27 Acceleron Pharma Inc Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
SMT202300222T1 (it) 2008-08-14 2023-09-06 Acceleron Pharma Inc Trappole di gdf
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
BRPI1010587A2 (pt) 2009-06-08 2019-04-09 Acceleron Pharma Inc. métodos para aumentar adipócitos termogênicos
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
WO2011025964A2 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
CA2818237C (en) 2009-11-18 2021-05-18 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
US9849192B2 (en) 2009-11-18 2017-12-26 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
EP2507381A4 (en) * 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
WO2011075636A2 (en) 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
BR112012021941A2 (pt) * 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
CN103298832A (zh) 2010-11-08 2013-09-11 阿塞勒隆制药公司 Actriia结合剂及其用途
JP2015502356A (ja) * 2011-11-30 2015-01-22 ウェルスタット ダイアグノスティクス，エルエルシー ５−ｆｕに関連するアッセイ、抗体、免疫原および組成物
TW201333040A (zh) * 2012-01-06 2013-08-16 Bioalliance Cv 抗－輸鐵蛋白受器之抗體及其使用方法
FR2987293B1 (fr) * 2012-02-27 2014-03-07 Michelin & Cie Procede et appareil pour realiser des objets tridimensionnels a proprietes ameliorees
CA2887037A1 (en) * 2012-10-02 2014-04-10 Rutgers, The State University Of New Jersey Specific delivery of toxins conjugated with antibodies to activated matriptase
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
BR112015010360A8 (pt) * 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
US20140171356A1 (en) * 2012-12-12 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Chemically immobilized wnt protein and methods of use
CA2922937A1 (en) 2013-09-05 2015-03-12 Duke University Nav1.7 antibodies and methods of using the same
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
PT3215530T (pt) 2014-11-07 2019-11-21 Sesen Bio Inc Anticorpos de il-6 melhorados
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
EP3419599A4 (en) 2016-02-23 2019-09-11 Sesen Bio, Inc. IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
JP7145374B2 (ja) 2016-03-18 2022-10-03 ラトガース ザ ステイト ユニバーシティー オブ ニュージャージー インビボでの切断可能連結部分によって抗マトリプターゼ抗体にコンジュゲートされた化学療法剤を用いる腫瘍細胞の標的化
EP3448875A4 (en) * 2016-04-29 2020-04-08 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
AU2018205484B2 (en) * 2017-01-06 2024-11-21 Sixal, Inc. Therapeutic anti-lgE antibodies and methods and compositions thereof
CN118909118A (zh) * 2017-09-07 2024-11-08 奥古斯塔大学研究所公司 程序性细胞死亡蛋白1抗体
US20220259298A1 (en) * 2019-07-12 2022-08-18 Kyoto University Neutralizing Antibody for Tooth Regeneration Treatment Targeting USAG-1 Molecule
CN112180099B (zh) * 2020-09-15 2022-07-29 江南大学附属医院 子宫内膜异位症血清标志物的应用
JP2025504020A (ja) 2022-01-28 2025-02-06 ジョージアミューン・インコーポレイテッド Ｐｄ－１アゴニストであるプログラム細胞死タンパク質１に対する抗体
CN115322258B (zh) * 2022-05-31 2024-08-13 武汉真福医药股份有限公司 一种单克隆抗体qkma-1g41及其应用
CN115304677B (zh) * 2022-06-19 2024-08-16 湖北真福医药有限公司 一种抗枯草芽孢杆菌纤溶酶的单克隆抗体qkma-9a10及应用
CN116712533B (zh) * 2023-07-03 2024-02-02 广东暨安特博生物科技有限公司 一种sostdc1蛋白在制备治疗皮肤病产品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2220912A1 (en) * 1995-06-05 1996-12-12 Gregg A. Hastings Human ccn-like growth factor
CA2416538A1 (en) * 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20040023356A1 (en) * 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
US20060002929A1 (en) * 2004-03-23 2006-01-05 Khare Sanjay D Monoclonal antibodies
WO2009131553A2 (en) * 2006-12-29 2009-10-29 Osteogenex Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
HRP20131167T1 (hr) * 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
PE20120475A1 (es) * 2009-05-12 2012-05-05 Pfizer Anticuerpos especificos para dkk-1

Also Published As

Publication number Publication date
CN101925611A (zh) 2010-12-22
CA2705879A1 (en) 2009-06-04
ZA201003578B (en) 2011-04-28
AU2008330125B2 (en) 2012-11-22
MA31918B1 (fr) 2010-12-01
CR11523A (es) 2010-12-16
WO2009070243A3 (en) 2009-10-29
EA201000844A1 (ru) 2011-10-31
IL205569A0 (en) 2010-12-30
BRPI0820387A2 (pt) 2015-05-26
WO2009070243A2 (en) 2009-06-04
JP2011504501A (ja) 2011-02-10
MX2010005656A (es) 2010-11-12
US8309092B2 (en) 2012-11-13
JP2014167002A (ja) 2014-09-11
US20120003237A1 (en) 2012-01-05
EP2220118A2 (en) 2010-08-25
US20090130114A1 (en) 2009-05-21
KR20100099193A (ko) 2010-09-10
JP5583591B2 (ja) 2014-09-03
US8043620B2 (en) 2011-10-25
AU2008330125A1 (en) 2009-06-04
TN2010000213A1 (en) 2011-11-11

Similar Documents

Publication Publication Date Title
CO6311002A2 (es) Agentes fijadores y epitopos wise
UY33124A (es) Agentes y epítopos enlazados a wise
BRPI0818874A2 (pt) Liberação de agentes ativos
UY3776Q (es) Reloj pulsera
EP3450425C0 (en) PERCARBOXYLIC ACID COMPOSITION
BRPI0807137A2 (pt) Agentes antiparasitários
BRPI0913945A2 (pt) agentes anti-inflamatórios
DK2178568T3 (da) Kontrastmidler
DK1985474T3 (da) Sættevogn
EP2135606A4 (en) MEDIUM AGAINST TIREDNESS
EP2160407A4 (en) NEUTRALIZING ANTIBODIES
FI20065652A0 (fi) Jallkine
EP2148354A4 (en) Electron source
DE502008001751D1 (de) Korrektor
ITMI20060591A1 (it) Innesto rapido
EP2214719A4 (en) Metallofullerene-DYE
DK2168197T3 (da) Membran-elektrode-enhed
DE112008002814A5 (de) Orthesengelenk
ES1066333Y (es) Reloj de pulsera.
DE602007012675D1 (de) Riemenspanner
ES1063619Y (es) Tuberia compensada
ATE439475T1 (de) Zwischenstück für leiteinrichtungen
DE202006015300U8 (de) Einteilige Knothilfe
ES1063530Y (es) Calzado
ES1063616Y (es) Calzado

Legal Events

Date Code Title Description
FA Application withdrawn